Altimmune shares plunge amid health concerns over obesity drug
Get Alerts ALT Hot Sheet
Join SI Premium – FREE
By Scott Kanowsky
Investing.com -- Shares in Altimmune, Inc. (NASDAQ: ALT) slumped by more than 54% on Tuesday, touching their lowest level since June, as concerns grew over the safety of its obesity drug following a mid-stage trial.
The U.S. clinical-stage company unveiled results from the study of its investigational therapy pemvidutide which showed that it helped patients reach average weight losses of 7.3%, 9.4% and 10.7% at various dosages.
But some participants in the trial discontinued their treatment because of gastrointestinal issues, with one subject in particular experiencing a "serious adverse event" of nausea and vomiting that required rehydration. Other cases were of "predominantly mild and moderate" severity, Maryland-based Altimmune said in a statement.
Treatment discontinuation rates were 24% in patients receiving pemvidutide and 28.2% in those taking a placebo, the group added.
The results come as Altimmune is aiming to bring a treatment to the potentially multi-billion dollar obesity drug market. Eli Lilly (NYSE: LLY) is also researching whether its diabetes drug can be used to treat obesity, while Novo Nordisk (NYSE: NVO) is already selling an injectable drug called Wegovy in the U.S.
You May Also Be Interested In
- Senate Committee Investigates Ozempic and Wegovy Costs - NYT
- Microsoft-backed Rubrik's stock jumps nearly 21% in NYSE debut
- T-Mobile to invest $950 million in venture with EQT to buy fiber optic network provider Lumos
Create E-mail Alert Related Categories
General News, InvestingSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!